previous arrow
next arrow

Editors' picks

SynBioBeta Report

2Q 2021 Synthetic Biology Venture Investment Report

The second quarter of 2021 was another record-breaking period for the synthetic biology startup community. Building on the extremely high amount of investment we saw in Q1 ($4.7 billion), Q2 also brought in more than $4...

Letter From the Editor: Leading the Future Is Never Easy

Last night, Zymergen, one of the first biology unicorns, announced that they would not generate revenues through 2022 and that their CEO was stepping down. Zymergen’s stock promptly fell 70% in after-hours trading. But...

Press releases

News by topic